Figure 1. Modification of Treg (A) and Th17 (B) populations at baseline and after one month of Tofacitinib treatment in RA patients.

Disclosure of Interests: viviana antonella pacucci: None declared, cristiano barbati: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Speakers bureau: Lilly, BMS, Celgene, Fulvia Ceccarelli: None declared, Silvia Mancuso: None declared, Cristina Garuti: None declared, cristiano alessandri Grant/research support from: Pfizer, fabrizio conti: Speakers bureau: BMS, batito: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, viviana antonella pacucci: None declared, cristiana barbati: None declared, None declared.

Disclosure of Interests:

Table 1. Outcome of contributory AEs/SAE at close of follow-up. SAEs classified as ‘expected’: DLT: dose limiting toxicity; N+V: nausea, vomiting.

Table 1. Outcome of contributory AEs/SAE at close of follow-up. SAEs classified as ‘expected’: DLT: dose limiting toxicity; N+V: nausea, vomiting.

Disclosure of Interests: Arthur Pratt Grant/research support from: Pfizer, GlaxoSmithKline, Stefan Siebert Grant/research support from: BMS, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, Janssen, Novartis, Michael Cole: None declared, Deborah Stocken: None declared, Stephen Kelly: None declared, Muddassar Shaikh: None declared, Amy Cranston: None declared, Miranda Morton: None declared, Jennifer Walker: None declared, Sheelagh Frame Employee of: Cyclacel Ltd., Wan-fai Ng: None declared, Chris Buckley Consultant of: Janssen, Pfizer, GSK, Galapagos, Gillead, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gillead, Janssen, Novartis, Pfizer, and UCB, Andrew Filer: None declared, John D Isaac Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Gillead, Janssen, Merck, Pfizer, Roche.

Disclosure of Interests: viavina antonella pacucci: None declared, cristiano barbati: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Speakers bureau: Lilly, BMS, Celgene, Fulvia Ceccarelli: None declared, Silvia Mancuso: None declared, Cristina Garuti: None declared, cristiano alessandri Grant/research support from: Pfizer, fabrizio conti: Speakers bureau: BMS, batito: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, viviana antonella pacucci: None declared, cristiana barbati: None declared, None declared.

Disclosure of Interests:

Table 1. Outcome of contributory AEs/SAE at close of follow-up. SAEs classified as ‘expected’: DLT: dose limiting toxicity; N+V: nausea, vomiting.

Table 1. Outcome of contributory AEs/SAE at close of follow-up. SAEs classified as ‘expected’: DLT: dose limiting toxicity; N+V: nausea, vomiting.

Disclosure of Interests: Arthur Pratt Grant/research support from: Pfizer, GlaxoSmithKline, Stefan Siebert Grant/research support from: BMS, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, Janssen, Novartis, Michael Cole: None declared, Deborah Stocken: None declared, Stephen Kelly: None declared, Muddassar Shaikh: None declared, Amy Cranston: None declared, Miranda Morton: None declared, Jennifer Walker: None declared, Sheelagh Frame Employee of: Cyclacel Ltd., Wan-fai Ng: None declared, Chris Buckley Consultant of: Janssen, Pfizer, GSK, Galapagos, Gillead, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gillead, Janssen, Novartis, Pfizer, and UCB, Andrew Filer: None declared, John D Isaac Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Gillead, Janssen, Merck, Pfizer, Roche.

Disclosure of Interests: Arthur Pratt Grant/research support from: Pfizer, GlaxoSmithKline, Stefan Siebert Grant/research support from: BMS, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Boehringer Ingelheim, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, Janssen, Novartis, Michael Cole: None declared, Deborah Stocken: None declared, Stephen Kelly: None declared, Muddassar Shaikh: None declared, Amy Cranston: None declared, Miranda Morton: None declared, Jennifer Walker: None declared, Sheelagh Frame Employee of: Cyclacel Ltd., Wan-fai Ng: None declared, Chris Buckley Consultant of: Janssen, Pfizer, GSK, Galapagos, Gillead, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gillead, Janssen, Novartis, Pfizer, and UCB, Andrew Filer: None declared, John D Isaac Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Gillead, Janssen, Merck, Pfizer, Roche.